Showcasing the Best of Welsh Business


Welsh Stem Cell Firm Gets the Go-Ahead for Heart Treatment


A biotech company founded by a Nobel prize winner has won the go-ahead from European regulators to begin the application process for conditional marketing authorization of a stem cell-based regenerative heart treatment.

Conditional approval, if granted, would allow Cardiff-based Cell Therapy to start selling its Heartcel product for regenerating damaged areas of heart while continuing to collect further clinical evidence about its effectiveness.

The European Medicines Agency (EMA) is keen to test such conditional approval procedures as part of a drive to evaluate promising life-saving treatments more swiftly than in the past.

Cell Therapy believes its medicine has the potential to reduce scarring of the heart muscle caused by a heart attack or heart failure.